EWTX News
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
Edgewise Therapeutics to Participate in Upcoming Investor Conferences Edgewise Therapeutics to Participate in Upcoming Investor ConferencesPR NewswireBOULDER, Colo., Nov. 9, 2026 BOULDER, Colo., Nov. 9, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage...
PR Newswire
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
Edgewise Therapeutics to Participate in Upcoming Investor Conferences Edgewise Therapeutics to Participate in Upcoming Investor ConferencesPR NewswireBOULDER, Colo., Nov. 9, 2026 BOULDER, Colo., Nov. 9, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage...
PR Newswire
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3...
PR Newswire
Edgewise Therapeutics Reports Third Quarter 2026 Financial Results
Edgewise Therapeutics Reports Third Quarter 2026 Financial Results Edgewise Therapeutics Reports Third Quarter 2026 Financial ResultsPR NewswireBOULDER, Colo., Nov. 4, 2026 Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain Phase 3 trial for...
PR Newswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireBOULDER, Colo., Nov. 2, 2026 BOULDER, Colo., Nov. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc...
PR Newswire
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.
Zacks
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400PR NewswireBOULDER, Colo., Oct. 8, 2026 Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at...
PR Newswire
Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?
Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.
Zacks
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireBOULDER, Colo., Oct. 1, 2026BOULDER, Colo., Oct. 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc...
PR Newswire
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500 Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500PR NewswireBOULDER, Colo., Sept. 22, 2026 - TheMoA that...
PR Newswire
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?
Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.
Zacks